Literature DB >> 26384496

Docking simulations suggest that all-trans retinoic acid could bind to retinoid X receptors.

Motonori Tsuji1, Koichi Shudo2, Hiroyuki Kagechika3.   

Abstract

Retinoid X receptors (RXRs) are ligand-controlled transcription factors which heterodimerize with other nuclear receptors to regulate gene transcriptions associated with crucial biological events. 9-cis retinoic acid (9cRA), which transactivates RXRs, is believed to be an endogenous RXR ligand. All-trans retinoic acid (ATRA) is a natural ligand for retinoic acid receptors (RARs), which heterodimerize with RXRs. Although the concentration of 9cRA in tissues is very low, ATRA is relatively abundant and some reports show that ATRA activates RXRs. We computationally studied the possibility of ATRA binding to RXRs using two different docking methods with our developed programs to assess the binding affinities of naturally occurring retinoids. The simulations showed good correlations to the reported binding affinities of these molecules for RXRs and RARs.

Entities:  

Keywords:  13-cis retinoic acid; 9-cis retinoic acid; All-trans retinoic acid; Docking simulation; Retinoic acid receptors; Retinoid X receptors

Mesh:

Substances:

Year:  2015        PMID: 26384496     DOI: 10.1007/s10822-015-9869-9

Source DB:  PubMed          Journal:  J Comput Aided Mol Des        ISSN: 0920-654X            Impact factor:   3.686


  35 in total

1.  The Protein Data Bank.

Authors:  H M Berman; J Westbrook; Z Feng; G Gilliland; T N Bhat; H Weissig; I N Shindyalov; P E Bourne
Journal:  Nucleic Acids Res       Date:  2000-01-01       Impact factor: 16.971

Review 2.  Retinoid receptors and therapeutic applications of RAR/RXR modulators.

Authors:  Albane le Maire; Susana Alvarez; Pattabhiraman Shankaranarayanan; Angel R de Lera; William Bourguet; Hinrich Gronemeyer
Journal:  Curr Top Med Chem       Date:  2012       Impact factor: 3.295

3.  Structural basis for a molecular allosteric control mechanism of cofactor binding to nuclear receptors.

Authors:  Judit Osz; Yann Brélivet; Carole Peluso-Iltis; Vincent Cura; Sylvia Eiler; Marc Ruff; William Bourguet; Natacha Rochel; Dino Moras
Journal:  Proc Natl Acad Sci U S A       Date:  2012-02-21       Impact factor: 11.205

4.  Antitumoral activity of 13-demethyl or 13-substituted analogues of all-trans retinoic acid and 9-cis retinoic acid in the human myeloid leukemia cell line HL-60.

Authors:  Yukari Mizuguchi; Akimori Wada; Kimie Nakagawa; Masayoshi Ito; Toshio Okano
Journal:  Biol Pharm Bull       Date:  2006-09       Impact factor: 2.233

5.  Crystal structure of the RAR-gamma ligand-binding domain bound to all-trans retinoic acid.

Authors:  J P Renaud; N Rochel; M Ruff; V Vivat; P Chambon; H Gronemeyer; D Moras
Journal:  Nature       Date:  1995-12-14       Impact factor: 49.962

6.  Asymmetry in the PPARgamma/RXRalpha crystal structure reveals the molecular basis of heterodimerization among nuclear receptors.

Authors:  R T Gampe; V G Montana; M H Lambert; A B Miller; R K Bledsoe; M V Milburn; S A Kliewer; T M Willson; H E Xu
Journal:  Mol Cell       Date:  2000-03       Impact factor: 17.970

7.  Polyunsaturated fatty acids including docosahexaenoic and arachidonic acid bind to the retinoid X receptor alpha ligand-binding domain.

Authors:  Johan Lengqvist; Alexander Mata De Urquiza; Ann-Charlotte Bergman; Timothy M Willson; Jan Sjövall; Thomas Perlmann; William J Griffiths
Journal:  Mol Cell Proteomics       Date:  2004-04-08       Impact factor: 5.911

Review 8.  Vitamin A and retinoid signaling: genomic and nongenomic effects.

Authors:  Ziad Al Tanoury; Aleksandr Piskunov; Cécile Rochette-Egly
Journal:  J Lipid Res       Date:  2013-02-24       Impact factor: 5.922

9.  Transactivation properties of retinoic acid and retinoid X receptors in mammalian cells and yeast. Correlation with hormone binding and effects of metabolism.

Authors:  E A Allegretto; M R McClurg; S B Lazarchik; D L Clemm; S A Kerner; M G Elgort; M F Boehm; S K White; J W Pike; R A Heyman
Journal:  J Biol Chem       Date:  1993-12-15       Impact factor: 5.157

10.  9-cis retinoic acid is a high affinity ligand for the retinoid X receptor.

Authors:  R A Heyman; D J Mangelsdorf; J A Dyck; R B Stein; G Eichele; R M Evans; C Thaller
Journal:  Cell       Date:  1992-01-24       Impact factor: 41.582

View more
  6 in total

1.  Antagonist-perturbation mechanism for activation function-2 fixed motifs: active conformation and docking mode of retinoid X receptor antagonists.

Authors:  Motonori Tsuji
Journal:  J Comput Aided Mol Des       Date:  2017-05-22       Impact factor: 3.686

Review 2.  The multi-faceted role of retinoid X receptor in bone remodeling.

Authors:  María P Menéndez-Gutiérrez; Mercedes Ricote
Journal:  Cell Mol Life Sci       Date:  2017-01-19       Impact factor: 9.261

3.  Anti-Chikungunya Virus Monoclonal Antibody That Inhibits Viral Fusion and Release.

Authors:  Uranan Tumkosit; Uamporn Siripanyaphinyo; Naokazu Takeda; Motonori Tsuji; Yusuke Maeda; Kriangsak Ruchusatsawat; Tatsuo Shioda; Hiroto Mizushima; Prukswan Chetanachan; Pattara Wongjaroen; Yoshiharu Matsuura; Masashi Tatsumi; Atsushi Tanaka
Journal:  J Virol       Date:  2020-09-15       Impact factor: 5.103

4.  Virtual Screening and Quantum Chemistry Analysis for SARS-CoV-2 RNA-Dependent RNA Polymerase Using the ChEMBL Database: Reproduction of the Remdesivir-RTP and Favipiravir-RTP Binding Modes Obtained from Cryo-EM Experiments with High Binding Affinity.

Authors:  Motonori Tsuji
Journal:  Int J Mol Sci       Date:  2022-09-20       Impact factor: 6.208

5.  Identifying the receptor subtype selectivity of retinoid X and retinoic acid receptors via quantum mechanics.

Authors:  Motonori Tsuji; Koichi Shudo; Hiroyuki Kagechika
Journal:  FEBS Open Bio       Date:  2017-02-05       Impact factor: 2.693

6.  Potential anti-SARS-CoV-2 drug candidates identified through virtual screening of the ChEMBL database for compounds that target the main coronavirus protease.

Authors:  Motonori Tsuji
Journal:  FEBS Open Bio       Date:  2020-05-29       Impact factor: 2.693

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.